The Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL

NCT07548255 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Intermediate-to-High-Risk Mantle Cell Lymphoma
the Efficacy and Safety

Interventions

DRUG: Sonrotoclax, Zanubrutinib Combined with Obinutuzumab

Sponsor

Ruijin Hospital